ADVBNasdaqServices-Medical LaboratoriesFiscal year ends June 30
Advanced Biomed Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026
$4.16+0.18 (+4.52%)
Close on Oct 19, 2026
- Market cap
- $6.51M
- P/E (TTM)
- 0.8
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2023 | FY2023 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 84.8% | |
| Return on assets | – | – | 36.5% | |
| Current ratio | – | – | 9.33 | |
| Diluted shares | – | – | 1M |
Cash use needs five years of cash flow figures
Advanced Biomed does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin5231.3%
×Asset turnover0.01×
×Equity multiplier2.32×
=Return on equity, FY202684.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 5231.3% | 0.01× | 2.32× | 84.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero$6.68M
- Cash generatingOperating cash flow above zero-$1.95M
- Return on assets improvedROA up on the prior year-73.1% → 29.2%
- Earnings backed by cashOperating cash flow above net income-$1.95M vs $6.68M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.16 → 9.33
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.01